DNA Methylation Drives Osteochondrogenic Reprogramming in Keloid Pathogenesis And Reveals Therapeutic Potential of Decitabine
M. Supp, PhD1,2; Caitlin Phillips, BS2; Jane Young, BS2; Jennifer M. Hahn, BS1; Heather M. Powell, PhD3,2; Sara Higginson, MD, FACS2
METRICS
Lian Zhang1,2*, Chenmei Liu1,2*, Xinyuan
Zhou3,4*, Yan Zhang1, Renliang He1,
Shuqing Zhao3,4, Chengcheng Deng1,2#,
Hongtao Li3,4,5#, Bin Yang1,2#
AUTHORS’ AFFILIATIONS:
1. Dermatology Hospital of Southern Medical
University, Guangzhou, Guangdong, 510091,
China
2. The First School of Clinical Medicine,
Southern Medical University, Guangzhou,
Guangdong, 510091, China
3. Institute of Brain Science and Brain-inspired
Research, Shandong First Medical University &
Shandong Academy of Medical Sciences, Jinan,
250117, China.
4. The Second Affiliated Hospital of Shandong
First Medical University & Shandong Academy
of Medical Sciences, Taian, 271000, China.
5. Shandong Institute of Brain Science and
Brain-inspired Research, Jinan, 250117, China.
Running Title
DNA Methylation Drives Osteochondrogenic Reprogramming in Keloid Pathogenesis and Reveals Therapeutic Potential of Decitabine
Word Count
250 words
The full text of this article is for subscribers. The title and abstract remain free to read.
